Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Aripiprazole

An atypical antipsychotic discovered in Japan in 1988 and approved in the United States in 2002, for schizophrenia and bipolar disorder. It was the first antipsychotic to act as a partial agonist at dopamine D2 receptors. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It is known as a 'dopamine stabiliser': where dopamine signalling is excessive it turns it down, where it is weak it boosts it, rather like a thermostat.

AripiprazoleGo to the active ingredient →
AripiprazoleActive ingredientAripiprazoleCat. No. P-A186-001CAS 129722-12-9

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.